Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
FLOW: Kidney, Cardiovascular, Mortality, Metabolic and Safety Results
Author(s): Richard Pratley Added: 1 year ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
ADA 24: FLOW Trial: Kidney Outcomes in Patients Treated with Semaglutide
Author(s): Vlado Perkovic Added: 1 year ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
THT 24: The ALT FLOW Early Feasibility Study
Author(s): Firas Zahr Added: 1 year ago
THT 24 - We are joined by Dr Firas Zahr (OHSU Knight Cardiovascular Institute Cardiology Clinic, US) to discuss the findings from the ALT FLOW Early Feasibility study (NCT03523416).The ALT FLOW Early Feasibility study aims to assess the initial clinical safety, functionality and effectiveness of a transcatheter atrial shunt system created by Edwards. 75 patients with symptomatic heart failure… View more

Heart Failure

Intervention
AHA 24 Late-Breaking Discussion: The FLOW Trial
Author(s): Harriette Van Spall , Added: 1 year ago
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD).The FLOW trial (NCT03819153) is designed to assess the effect of… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Added: 1 year ago

Imaging & Diagnostics
LINC 25: The GRIFFIN Study
Author(s): Tatsuya Nakama Added: 1 year ago
LINC 2025 - Outcomes from the GRIFFIN study suggest post-procedural functional flow reserve (FFR) could be a useful predictor of restenosis after drug-coated balloon (DCB) angioplasty for superficial femoral artery (SFA) lesions. Restenosis patients showed significantly lower FFR values than non-restenosis patients, and the study resulted in a good FFR cut-off value of restenosis after DCB… View more

Intervention

Vascular Disease and Surgery
Job title: Consultant Cardiologist
Job title: Professor of Cardiac Ultrasound
DELINEATE-Regurgitation: AI Accurately Classifies Valvular Regurgitation and Predicts MR Progression
Added: 6 months ago Source:  Radcliffe Cardiology
The classification and risk stratification of aortic, mitral, and tricuspid regurgitation present significant clinical challenges, with diagnosis often subject to interobserver variability. The DELINEATE-Regurgitation study investigated a novel artificial intelligence (AI) system designed to provide accurate, reproducible echocardiographic assessment of valvular regurgitation and to stratify the… View more

Digital Health

Guidelines & Statements
David Newby
Dr David Newby graduated from the University of Southampton with a Bachelor of Science and Bachelor of Medicine degree in 1991. Dr Newby is British Heart Foundation John Wheatley Chair of Cardiology at the University of Edinburgh, Director of Research and Development for NHS Lothian, Director of the Wellcome Trust Clinical Research Facility, Director of the Clinical Research Imaging Centre, and a… View more